Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia

Zelalem Temesgen, Mariam Assi, Paschalis Vergidis, Stacey A. Rizza, Philippe R. Bauer, Brian W. Pickering, Raymund R. Razonable, Claudia R. Libertin, Charles D. Burger, Robert Orenstein, Hugo E. Vargas, Bharath Raj Varatharaj Palraj, Ala S. Dababneh, Gabrielle Chappell, Dale Chappell, Omar Ahmed, Reona Sakemura, Cameron Durrant, Saad S. Kenderian, Andrew D. Badley
doi: https://doi.org/10.1101/2020.06.08.20125369
Zelalem Temesgen
1Division of Infectious Diseases, Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Temesgen.zelalem@mayo.edu Badley.Andrew@mayo.edu kenderian.saad@mayo.edu
Mariam Assi
1Division of Infectious Diseases, Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paschalis Vergidis
1Division of Infectious Diseases, Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stacey A. Rizza
1Division of Infectious Diseases, Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe R. Bauer
2Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian W. Pickering
3Department of Anesthesia and Critical Care Medicine, Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raymund R. Razonable
1Division of Infectious Diseases, Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia R. Libertin
4Division of Infectious Diseases, Mayo Clinic, Jacksonville, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles D. Burger
5Division of Pulmonary Medicine, Mayo Clinic, Jacksonville, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Orenstein
6Division of Infectious Diseases, Mayo Clinic, Scottsdale, AZ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hugo E. Vargas
7Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, AZ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bharath Raj Varatharaj Palraj
1Division of Infectious Diseases, Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ala S. Dababneh
1Division of Infectious Diseases, Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabrielle Chappell
8Humanigen, Inc, Burlingame, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dale Chappell
8Humanigen, Inc, Burlingame, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Omar Ahmed
8Humanigen, Inc, Burlingame, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reona Sakemura
9T Cell Engineering, Mayo Clinic, Rochester, MN
10Division of Hematology, Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cameron Durrant
8Humanigen, Inc, Burlingame, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saad S. Kenderian
9T Cell Engineering, Mayo Clinic, Rochester, MN
10Division of Hematology, Mayo Clinic, Rochester, MN
11Department of Immunology, Mayo Clinic, Rochester, MN
12Department of Molecular Medicine, Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Temesgen.zelalem@mayo.edu Badley.Andrew@mayo.edu kenderian.saad@mayo.edu
Andrew D. Badley
1Division of Infectious Diseases, Mayo Clinic, Rochester, MN
12Department of Molecular Medicine, Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Temesgen.zelalem@mayo.edu Badley.Andrew@mayo.edu kenderian.saad@mayo.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background In COVID-19, high levels of granulocyte macrophage-colony stimulating factor (GM-CSF) and inflammatory myeloid cells correlate with disease severity, cytokine storm, and respiratory failure. With this rationale, we used lenzilumab, an anti-human GM-CSF monoclonal antibody, to treat patients with severe and critical COVID-19 pneumonia.

Methods Hospitalized patients with COVID-19 pneumonia and risk factors for poor outcomes were treated with lenzilumab 600 mg intravenously for three doses through an emergency single-use IND application. Patient characteristics, clinical and laboratory outcomes, and adverse events were recorded. All patients receiving lenzilumab through May 1, 2020 were included in this report.

Results Twelve patients were treated with lenzilumab. Clinical improvement was observed in 11 out of 12 (92%), with a median time to discharge of 5 days. There was a significant improvement in oxygenation: The proportion of patients with SpO2/FiO2 < 315 at the end of observation was 8% vs. compared to 67% at baseline (p=0.00015). A significant improvement in mean CRP and IL-6 values on day 3 following lenzilumab administration was also observed (137.3 mg/L vs 51.2 mg/L, p = 0.040; 26.8 pg/mL vs 16.1 pg/mL, p = 0.035; respectively). Cytokine analysis showed a reduction in inflammatory myeloid cells two days after lenzilumab treatment. There were no treatment-emergent adverse events attributable to lenzilumab, and no mortality in this cohort of patients with severe and critical COVID-19 pneumonia.

Conclusions In high-risk COVID-19 patients with severe and critical pneumonia, GM-CSF neutralization with lenzilumab was safe and associated with improved clinical outcomes, oxygen requirement, and cytokine storm.

Competing Interest Statement

Acknowledgements: Lenzilumab was supplied by Humanigen, Inc. This work was supported through grants from K12CA090628 (SSK), Mayo Clinic K2R Career Development Program (SSK), ADB is supported by Grants AI 110173 and AI120698 from NIAID, 109593-62-RGRL from Amfar, and the HH Sheikh Khalifa Bin Zayed Al-Nahyan named professorship from Mayo Clinic. Disclosures: SSK is an inventor on patents in the field of CAR immunotherapy that are licensed to Novartis (through an agreement between Mayo Clinic, University of Pennsylvania, and Novartis) and Mettaforge (through Mayo Clinic). RS and SSK RS are inventors on patents in the field of CAR immunotherapy that are licensed to Humanigen (through Mayo Clinic). SSK receives research funding from Kite, Gilead, Juno, Celgene, Novartis, Humanigen, MorphoSys, Tolero, Sunesis, and Lentigen. SSK has participated in advisory boards with Kite, Juno, Novartis, and Humanigen. ADB is a consultant for Abbvie, is on scientific advisory boards for Nference and Zentalis, and is founder and President of Splissen therapeutics. GC, DC, OA, CD are employed by Humanigen. The rest of the authors declare no relevant disclosures.

Clinical Trial

Research details the compassionate use of lenzilumab (novel anti-human-GM-CSF monoclonal antibody) in hospitalized patients with severe or critical COVID-19 pneumonia through emergency single-use IND applications treated at the Mayo Clinics located in the US. Lenzilumab is one of the few novel immunomodulatory agents in late stage development and this research served as the basis for the ongoing phase 3 registration study (NCT04351152).

Funding Statement

No funding was provided for the compassionate use treatment of these subjects with severe or critical COVID-19. Lenzilumab was supplied by Humanigen, Inc. for the compassionate use treatment of COVID-19 subjects by investigators at the Mayo Clinics.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Hospitalized patients with COVID-19, confirmed by reverse transcriptase-polymerase chain reaction for the SARS-CoV-2, and radiographic findings consistent with COVID-19 pneumonia were considered for treatment with lenzilumab through an emergency IND program. Active systemic infection with bacteria, fungi, or other viruses, was an exclusion criterion. All patients received lenzilumab 600 mg administered via a 1-hour intravenous infusion every 8 hours for a total of three doses (1800 mg). A request for lenzilumab under FDA emergency use IND was submitted to the FDA in accordance with agency guidelines (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-investigational-drug-or-biologic). Informed consent and Institutional review board approval was obtained for each patient at the Mayo Clinic.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data is included in the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted June 14, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia
Zelalem Temesgen, Mariam Assi, Paschalis Vergidis, Stacey A. Rizza, Philippe R. Bauer, Brian W. Pickering, Raymund R. Razonable, Claudia R. Libertin, Charles D. Burger, Robert Orenstein, Hugo E. Vargas, Bharath Raj Varatharaj Palraj, Ala S. Dababneh, Gabrielle Chappell, Dale Chappell, Omar Ahmed, Reona Sakemura, Cameron Durrant, Saad S. Kenderian, Andrew D. Badley
medRxiv 2020.06.08.20125369; doi: https://doi.org/10.1101/2020.06.08.20125369
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia
Zelalem Temesgen, Mariam Assi, Paschalis Vergidis, Stacey A. Rizza, Philippe R. Bauer, Brian W. Pickering, Raymund R. Razonable, Claudia R. Libertin, Charles D. Burger, Robert Orenstein, Hugo E. Vargas, Bharath Raj Varatharaj Palraj, Ala S. Dababneh, Gabrielle Chappell, Dale Chappell, Omar Ahmed, Reona Sakemura, Cameron Durrant, Saad S. Kenderian, Andrew D. Badley
medRxiv 2020.06.08.20125369; doi: https://doi.org/10.1101/2020.06.08.20125369

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (420)
  • Anesthesia (97)
  • Cardiovascular Medicine (896)
  • Dentistry and Oral Medicine (169)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (405)
  • Epidemiology (8764)
  • Forensic Medicine (4)
  • Gastroenterology (404)
  • Genetic and Genomic Medicine (1857)
  • Geriatric Medicine (177)
  • Health Economics (387)
  • Health Informatics (1284)
  • Health Policy (642)
  • Health Systems and Quality Improvement (490)
  • Hematology (206)
  • HIV/AIDS (392)
  • Infectious Diseases (except HIV/AIDS) (10543)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1748)
  • Nursing (102)
  • Nutrition (265)
  • Obstetrics and Gynecology (342)
  • Occupational and Environmental Health (459)
  • Oncology (962)
  • Ophthalmology (281)
  • Orthopedics (107)
  • Otolaryngology (176)
  • Pain Medicine (117)
  • Palliative Medicine (41)
  • Pathology (263)
  • Pediatrics (556)
  • Pharmacology and Therapeutics (264)
  • Primary Care Research (218)
  • Psychiatry and Clinical Psychology (1841)
  • Public and Global Health (3975)
  • Radiology and Imaging (650)
  • Rehabilitation Medicine and Physical Therapy (341)
  • Respiratory Medicine (534)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (196)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (79)